Kawasaki disease (KD) is an acute systemic characterized by predominant damage to small and medium-sized arteries with the development of destructive-proliferative vasculitis, coronary (CA) visceral arteries. In addition symptoms included in diagnostic criteria for KD, other clinical manifestations are observed Article. Facial nerve KD a rare but serious manifestation which can be marker severe CA damage. Authors represent their own case report 5-months-old male patient late diagnosis...

The aim of this study was to investigate the efficacy etanercept treatment and identify predictors response therapy within 12 months in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations.A total 197 were enrolled study. Response assessed using ACRPedi 30/50/70/90 criteria, Wallace Juvenile Arthritis Disease Activity Score 71 (JADAS-71). Univariate multivariate logistic regression analyses performed potential baseline factors associated different JIA...

Management protocol for patients with juvenile arthritis was developed the assistance of workers from two largest educational scientific research institutions — Scientific Centre Children Health and I.M. Sechenov First Moscow Medical State University. The authors summarized international their own long-term clinical experience showed modern data on etiology, pathogenesis, diagnostics treatment arthritis.

The article describes the international experience in monitoring of patients with juvenile idiopathic arthritis. main goal most existing registers children arthritis is to evaluate various aspects effectiveness and safety genetic engineering biological drugs comparison methotrexate. No results from analysis as a tool for long-term disease medical care systemic have been found available literature.

The article describes the monitoring of severe cryopyrin-associated syndrome (syndrome CINCA/NOMID). following clinical case indicates successful application homogeneous antibodies to interleukin 1 — canakinumab in patient with chronic neurologic dermatic articular syndrome. Fever, rush and pain completely jugulated, contractures articulation joints decreased a week since beginning treatment. In 8 weeks therapy movements affected almost restored, boy could stay, spell simple words;...

The results of the retrospective study evaluating efficacy and safety tocilizumab treatment in 75 patients with severe systemic-onset juvenile idiopathic arthritis refractory to standard immunosuppressive therapy are presented paper. Inactive disease was documented 64% after 6 months 73% 12 months. Adverse events manifested as mild moderate infections well laboratory abnormalities: leukopenia, neutropenia, elevated aminotransferase levels.

Objective: Our aim was to study features of the drug therapy children with systemic juvenile idiopathic arthritis (sJIA). Methods: We conducted a retrospective data analysis included in Register sJIA cases, for period from 2002 2015. Results: The indicators 384 are studied. Prior diagnosis verification, all patients were prescribed intake antipyretic agents, 98% — antibiotics. After diagnosis, non-steroidal anti-inflammatory drugs (NSAIDs) intaken by 282 (73.4%) patients: diclofenac sodium...

Background. Blocking of B lymphocytes producing autoantibodies in systemic lupus erythematosus (SLE) may be an effective strategy for pathogenetic treatment, including children. Objective: Our aim was to assess the efficacy and safety rituximab treatment (chimeric monoclonal antibodies CD20) children with severe SLE refractory glucocorticosteroids immunosuppressants. Methods. We studied case histories admitted rheumatology department SCCH between 2004 2013. The results were assessed by...

Objective : Our aim was to study demographic and clinical characteristics of patients with systemic juvenile idiopathic arthritis (sJIA), timing diagnosis routing the children after onset disease according All-Russian Register Union Pediatricians Russia. Methods Retrospective (1998–2015) analyzing indicators from 384 sJIA. Results The majority live in Central Volga Federal Districts — 157 (40.9%) 68 (17.7%) patients, respectively. ratio girls boys is 1.25:1; 281 (73.2%) got sick under age 5....

Aim : to assess efficacy and safety of «changeover» the second genetically engineered biological agent (GEBA) in patients with juvenile idiopathic arthritis (JIA) resistance or intolerability first GEBA. Patients methods results retrospective observational research GEBA 136 various variants JIA aged from 1 17 years old primary resistance, partial effect loss other agents are shown this article. Among those 41 patient have systemic 95 — without extra-articular involvement. In 32 involvement...

The article contains results of the study efficacy and safety adalimumab treatment given to 110 patients with juvenile idiopathic arthritis (JIA) eye-lesions, refractory classical immunosuppressive treatment. Follow up period was from 3 months 1 year long. dosage regimen as follows — subcutaneous injection Adalimumab 40 mg once in 2 weeks. Against background anti-TNF agents clinical remission, decrease normalization lab parameters disease activity, lower degree disability, quality life...

Morozov Children’s City Clinical Hospital, almost in the first months of development COVID-19 epidemic, began to admit not only patients with acute infection, but mainly combined comorbid pathology. Based on a retrospective analysis 290 medical records children hospitalized at an admitted hospital predominantly pathology was carried out between April 2020 and September 2020. Six these had fatal outcome. Most were 3 years life (38,4 %) puberty (37,3 %). The diagnoses varied: pneumonia — 41...

Systemic-onset juvenile arthritis (sJIA) is an acute and severe disease characterized by systemic inflammation, extra-articular manifestations. Until now, sJIA considered to be a diagnosis of “exception” requiring careful differential coupled with number other diseases. The purpose this research was evaluate the demographic features sJIA, analyze clinical laboratory data, patients’ compliance diagnostic criteria according International League Associations for Rheumatology's (ILAR)...

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease of unknown etiology characterized by hyperproduction autoantibodies. The problems timely diagnosis and identification predictors an unfavorable outcome SLE are relevant due to the variable clinical picture high risk 5-year mortality in absence treatment. purposes this research were assess frequency various variants onset, identify trigger factors contributing development analyze degree activity children. Materials methods...

Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease (AID) caused by mutations in MEFV gene. The purpose of this research was to investigate clinical variability and potential genotypic phenotypic correlations children with clinically verified FMF gene City Moscow, Russia. Materials methods used: among 188 pediatric patients suspected AIDs, were identified 9 through sequencing. In order confirm diagnosis, evaluated according modified Tel-Hashomer criteria...

<h3>Background</h3> Anti-TNF biologics are highly effective and widely used in clinical practice for the treatment of JIA. However, some children lack response with few reliable predictors a good or poor to found [1–3]. As picture patterns significantly differ 7 JIA subclasses, we propose therapy each category. <h3>Objectives</h3> To identify laboratory parameters associated etanercept 12 months patients different <h3>Methods</h3> Patients from four categories (n=195) were divided groups...

Systemic Juvenile Idiopathic Arthritis (sJIA) is chronic disease. Some patients are resistant to standard immunosupressivetherapy and anti IL6 treatment. of these have autoinflammatory

Purpose of the research was to study structure cardiovascular system (CVS) lesions, risk factors and predictors for adverse outcomes in children with Kawasaki disease (KD). Materials methods used: a single-center retrospective cohort 188 patients (126 boys/62 girls) aged 2 months 11 years old KD 2014-2019. Depending on outcome disease, two groups were identified: those recovery (171/188, 91%), unfavorable (17/188, 9%) form persistent coronary artery aneurysms (CAA) 12 (6.4%) cases death 5...

“Turning the complicated problems into new opportunities and constantly maintaining confidence in future” - these are principles Morozov Children’s Hospital its entire large team approach celebration of 120th anniversary with. The history is a constant movement forward, highest professionalism courage staff, achievements victories. As today, one largest multidisciplinary hospitals not only Moscow, but also overall Russia, where patients expect get best professional experience coupled with...

Treatment of juvenile idiopathic arthritis (JIA) is one the most complex and urgent problems rheumatology. Objective : We undertook a study to evaluate effectiveness safety long-term therapy with etanercept in patients JIA without systemic manifestations. Methods Patients were divided into 2 groups. main group (n = 197) received etanercept, comparison 200) - methotrexate. The was assessed by American College Rheumatology (ACR) criteria Wallace's for clinical remission (CR) 4-year JADAS71...

The case of early debut and heavy course juvenile idiopathic arthritis in the patient at age 1 year 8 months, associated with uveitis refractory to therapy by methotrexate nonsteroid antiinflammatory preparations is presented. given clinical example shows high therapeutic efficiency adalimumab. To 8th week treatment inflammatory changes conjunctiva were stopped, 12th stage inactive illness was registered, i.e. had no joints, activity signs, increase laboratory indicators activity. Duration...

Background : Addition of genetically engineered biological agents in the paradigm juvenile idiopathic arthritis (JIA) treatment significantly increased efficacy antirheumatic therapy patients with this severe chronic disease. Objective . Our aim was to assess and safety etanercept JIA without systemic manifestations. Methods The open prospective study included manifestations treated etanercept. carried out on basis rheumatological department Scientific Center Children's Health (Moscow)...

This article describes a case of successfully used tocilizumab (interleukin 6 receptors monoclonal antibodies) in two-year patient with severe systemic juvenile idiopathic arthritis resistant to oral and parenteral glucocorticoids, nonsteroidal anti-inflammatory drugs, methotrexate. Just after the first injection tocilizumab, fever pain ceased, morning stiffness decreased significantly; laboratory disease activity indices normalized by 4th week drug use; 16th inflammatory changes joints...